Home › Catalysts
Quarter catalyst calendar
What lands in 4Q 2026, a look ahead to 1Q 2027, and the rest of the next twelve months below that. Dates are the company's own guidance as reported in our coverage — most are windows rather than fixed days, and each row says which it is. Click any catalyst to read the latest post on it.
Updated October 10, 2026 · 262 events
No catalysts match these filters.
This quarter · dated
49the company named a day or a month
- Oct 2026 IVVD Avoid VYD2311 topline thesis-defining
- Oct 2026 TLSA Avoid Intranasal foralumab na-SPMS topline thesis-defining
- Oct–Nov 2026 IONS Watch Ionis corporate update material
- Oct 2026 EIKN Watch EIK1003 Ph1 readout notable
- Oct 14, 2026 VSTM Spec buy VS-7375 interim major
- Oct 20, 2026 RCUS Spec buy Casdatifan Ph3 interim major
- Oct 22, 2026 HRMY Watch WAKIX litigation ruling material
- Oct 23–27, 2026 TNGX Buy vopimetostat + RAS ON Ph1 major
- Oct 23, 2026 CATX Hold VMT-α-NET interim material
- Oct 23–27, 2026 INBX Spec buy INBRX-106 readout material
- Oct 23–27, 2026 NVCT Spec buy NXP200 Ph1 readout material
- Oct 23, 2026 EIKN Watch EIK1005 Ph1 readout notable
- Oct 24, 2026 CLYM Buy Budoprutug Ph2 topline thesis-defining
- Oct 24, 2026 CMPX Avoid Tovecimig readout notable
- Oct 25, 2026 NBP Spec buy Givastomig Ph1 readout major
- Oct 25, 2026 ANAB Spec buy AZUR-1 readout notable
- Oct 26, 2026 IONS Watch Bepirovirsen PDUFA date material
- Oct 26, 2026 EIKN Watch TeLuRide-005 NSCLC readout notable
- Oct 26, 2026 VNDA Avoid HETLIOZ® litigation ruling notable
- Nov 2026 PEPG Spec buy PGN-EDODM1 topline thesis-defining
- Nov 2026 RVMD Watch RASONQUE daraxonrasib corporate update material
- Nov 2026 AXSM Watch AUVELITY corporate update notable
- Nov 2026 HRMY Watch WAKIX / MSN License Agreement notable
- Nov 2026 NRXP Spec buy Corporate financials filing notable
- Nov 2, 2026 RXRX Watch REC-4881 Ph1 readout major
- Nov 7, 2026 MDNAF Hold MDNA11 SITC Ph1 topline major
- Nov 9, 2026 ARTV Spec buy AlloNK + rituximab ACR interim material
- Nov 10, 2026 NRXP Spec buy NRX-100 ANDA FDA decision thesis-defining
- Nov 12–14, 2026 KTTA Buy PAS-004 Ph1 topline thesis-defining
- Nov 14, 2026 SMMT Buy ivonescimab NSCLC PDUFA date thesis-defining
- Nov 14, 2026 SMMT Buy ivonescimab NSCLC FDA decision thesis-defining
- Nov 16, 2026 IMNM Watch BMS resale registration filing notable
- Nov 22, 2026 CAPR Spec buy Deramiocel PDUFA date thesis-defining
- Nov 22, 2026 KROS Watch Capricor deramiocel FDA decision material
- Nov 28, 2026 PYPD Spec buy D-PLEX₁₀₀ PDUFA date thesis-defining
- Nov 30, 2026 COGT Buy Bezuclastinib + sunitinib GIST PDUFA thesis-defining
- Dec 2026 ADCT Watch ZYNLONTA + glofitamab topline thesis-defining
- Dec 2026 KOD Hold KSI-101 Ph3 topline thesis-defining
- Dec 2026 CGEM Buy CLN-978 readout material
- Dec 2026 PRLD Watch Incyte JAK2V617F next-gen readout material
- Dec 2026 ZNTL Spec buy Azenosertib China decision material
- Dec 2026 NRSN Avoid PrimeC filing notable
- Dec 2026 NRSN Avoid NDS Canada filing notable
- Dec 12, 2026 ANAB Spec buy Imsidolimab FDA approval material
- Dec 12, 2026 VNDA Avoid Imsidolimab FDA approval material
- Dec 18, 2026 BDTX Watch Black Diamond corporate China decision material
- Dec 23, 2026 LEGN Spec buy anito-cel Arcellx PDUFA date thesis-defining
- Dec 29, 2026 TLSA Avoid Intranasal foralumab MSA FDA decision material
- Dec 30, 2026 COGT Buy Bezuclastinib NonAdvSM PDUFA date thesis-defining
This quarter · guided to 4Q 2026
83
committed to the quarter, no finer date given
- 4Q 2026 AKBA Spec buy Vafseo VOCAL topline thesis-defining
- 4Q 2026 ANNX Watch Vonaprument Ph3 topline thesis-defining
- 4Q 2026 EYPT Hold DURAVYU LUCIA topline thesis-defining
- 4Q 2026 GUTS Spec buy Revita pivotal topline thesis-defining
- 4Q 2026 HELP Spec buy HLP003 Ph3 topline thesis-defining
- 4Q 2026 IDYA Watch IDE849 Ph1 topline thesis-defining
- 4Q 2026 IRON Watch Bitopertin topline thesis-defining
- 4Q 2026 LQDA Watch YUTREPIA FDA decision thesis-defining
- 4Q 2026/1Q 2027 OCS Spec buy Licaminlimab pivotal topline thesis-defining
- 4Q 2026 PMVP Spec buy Rezatapopt topline thesis-defining
- 4Q 2026 VIR Buy ECLIPSE 1 Ph3 topline thesis-defining
- 4Q 2026 ZBIO Spec buy Obexelimab SLE Ph2 topline thesis-defining
- 4Q 2026 ZURA Watch Tibulizumab TibuSHIELD topline thesis-defining
- 4Q 2026 ACHV Watch Cytisinicline smoking cessation NDA filing major
- 4Q 2026 ACRS Buy bosakitug Ph2 topline major
- 4Q 2026 ACRS Buy bosakitug topline major
- 4Q 2026 AXSM Watch solriamfetol ENGAGE Ph3 topline major
- 4Q 2026 BCYC Watch Zelenectide pevedotin Ph2 readout major
- 4Q 2026 BDTX Watch Silevertinib FDA feedback major
- early 4Q 2026 CLNN Hold CNM-Au8 ALS NDA filing major
- 4Q 2026 FATE Watch FT819 Ph1 readout major
- 4Q 2026 GPCR Hold aleniglipron Ph2 topline major
- 4Q 2026 KYTX Buy Miv-cel BLA filing major
- 4Q 2026 ORKA Buy ORKA-001 Ph3 topline major
- 4Q 2026 SPRB Buy TA-ERT tralesinidase alfa BLA filing major
- 4Q 2026 VYGR Watch VY7523 interim major
- 4Q 2026/1Q 2027 ACHV Watch Cytisinicline smoking cessation corporate update material
- 4Q 2026 ADCT Watch ZYNLONTA monotherapy MZL readout material
- 4Q 2026 ALLO Spec buy ALLO-329 Ph1 interim material
- 4Q 2026 ANNX Watch Tanruprubart BLA filing material
- 4Q 2026 BDTX Watch Silevertinib Ph2 readout material
- 4Q 2026 CLYM Buy Budoprutug SC formulation Ph1 readout material
- 4Q 2026 CMPX Avoid Tovecimig BLA filing material
- 4Q 2026 ENTA Spec buy EDP-978 Ph1 topline material
- 4Q 2026 EWTX Watch sevasemten topline material
- 4Q 2026 FATE Watch Autolus obe-cel CARLYSLE readout material
- 4Q 2026 IPSC Spec buy CNTY-813 IND filing material
- 4Q 2026 KYMR Buy KT-579 Ph1 readout material
- 4Q 2026 KYTX Buy SPS BLA filing material
- 4Q 2026 MLTX Watch Sonelokimab PsA topline material
- 4Q 2026 NAMS Watch PREVAIL obicetrapib interim material
- 4Q 2026 ORKA Buy ORKA-001 readout material
- 4Q 2026 PTGX Buy Takeda/J&J milestone payments FDA decision material
- 4Q 2026 SNDX Buy Revuforj 4Q26 revumenib readout material
- 4Q 2026 ABSI Buy ABS-201 Endometriosis Ph2 start notable
- 4Q 2026 ACRS Buy ATI-9494 IND filing notable
- 4Q 2026 BDTX Watch BH-30643 BlossomHill FDA feedback notable
- 4Q 2026 CABA Buy SSc-ILD registrational study pivotal start notable
- 4Q 2026 CGEM Buy CLN-049 Ph2 readout notable
- 4Q 2026 CMPS Buy COMP360 TRD NDA filing notable
- 4Q 2026 CMPX Avoid CTX-8371 Ph1 readout notable
- 4Q 2026 CMPX Avoid CTX-10726 Ph1 readout notable
- 4Q 2026 CNTB Watch Rademikibart FDA feedback notable
- 4Q 2026 CUE Buy CUE-221 Ph2b start notable
- 4Q 2026 ENTA Spec buy RESOLVE Ph2b start notable
- 4Q 2026 EWTX Watch EDG-7500 Ph3 start notable
- 4Q 2026 EWTX Watch aficamten competitor sNDA filing notable
- 4Q 2026 FATE Watch Kyverna miv-cel BLA filing notable
- 4Q 2026 FDMT Watch 4D-710 AEROW Ph1 readout notable
- 4Q 2026/1Q 2027 GLUE Buy MRT-8102 GFORCE-3 Ph2 start notable
- 4Q 2026 GLUE Buy MRT-9347 IND filing notable
- 4Q 2026 GPCR Hold ACCG-3535 / combination trial Ph1 notable
- 4Q 2026 HRMY Watch BP-205 interim notable
- 4Q 2026 IDYA Watch IDE892/MTAP/CDKN2A/KRAS readout notable
- 4Q 2026 INBX Spec buy Ozekibart FDA feedback notable
- 4Q 2026 IRON Watch Selcodebart Ph2 readout notable
- 4Q 2026 IRON Watch DISC-3405 Ph1 readout notable
- 4Q 2026 KZIA Watch Paxalisib HR trial start notable
- early 4Q 2026 NBP Spec buy Givastomig Ph3 start notable
- 4Q 2026 PRLD Watch PRT13722 trial start notable
- 4Q 2026 RARE Buy UX701 Ph1 readout notable
- 4Q 2026 RCUS Spec buy ARC-20 cohorts cas+axitinib trial start notable
- 4Q 2026 REPL Buy RP2 readout notable
- 4Q 2026 RNTX Watch LTI-03 Ph2 interim notable
- 4Q 2026 SABS Spec buy SAB-142 enrollment done notable
- 4Q 2026 SCYX Watch SCY-770 Ph2 start notable
- 4Q 2026 SNDX Buy Niktimvo MAXPIRe axatilimab Ph2 readout notable
- 4Q 2026 SNDX Buy Niktimvo cGVHD axatilimab Ph2 readout notable
- 4Q 2026 SYRE Hold SKYWAY PsA and axSpA sub-studies notable
- 4Q 2026 VERA Buy Atacicept PIONEER Ph2 readout notable
- 4Q 2026 VRDN Buy TSHR program IND filing notable
- 4Q 2026 VYGR Watch VY1706 trial start notable
- late 4Q 2026 SLDB Spec buy SGT-003 FDA feedback thesis-defining
Could land this quarter — no finer guidance
56
a six- to twelve-month window that overlaps this quarter by construction; shown in full on each company's page
- 2026 BCTX Avoid Bria-IMT + CPI Ph3 interim major
- 2026 NKTX Watch NKX019 Ntrust-1 readout major
- 2026 TNGX Buy Vopimetostat monotherapy lung cancer Ph1 material
- 2026 IBRX Buy QUILT-2.005 sBLA filing notable
- 2026 KYTX Buy Miv-cel Ph1 readout notable
- 2026 STRO Buy STRO-006 IND filing notable
- 2H 2026 BIOA Hold BGE-102 topline thesis-defining
- 2H 2026 CHRS Hold Casdozokitug Ph2 topline thesis-defining
- 2H 2026 GNLX Watch Olvi-Vec OnPrime Ph3 topline thesis-defining
- 2H 2026 INKT Watch agenT-797 topline thesis-defining
- 2H 2026 ABSI Buy ABS-201 AGA interim major
- 2H 2026 ACRS Buy ATI-052 Ph1 topline major
- 2H 2026 BBOT Spec buy BBO-10203 readout major
- 2H 2026 BBOT Spec buy BBOT pipeline BBO-11818 Ph1 readout major
- 2H 2026 GERN Spec buy Imetelstat IMpactMF interim major
- 2H 2026 INAB Watch INB-400 FDA feedback major
- 2H 2026 INMB Watch CORDStrom/Ebstrocel MAA filing major
- 2H 2026 BBOT Spec buy BBO-11818 Ph1 interim material
- 2H 2026 DBVT Watch Viaskin Peanut Toddlers 1-3yo BLA material
- 2H 2026 ERAS Watch ERAS-4001 Ph1 interim material
- 2H 2026 JANX Buy JANX011 Ph1 interim material
- 2H 2026 VRDN Buy VRDN-008 Ph1 readout material
- 2H 2026 AGMB Spec buy Ontunisertib Ph2b start notable
- 2H 2026 ANNX Watch ANX1502 POC readout notable
- 2H 2026 ARVN Spec buy ARV-393 Ph1 interim notable
- 2H 2026 ARVN Spec buy ARV-806 KRAS readout notable
- 2H 2026 ENTA Spec buy EPS-3903 IND filing notable
- 2H 2026 INAB Watch INB-619 readout notable
- 2H 2026 INSM Watch ARIKAYCE Japan filing notable
- 2H 2026 NTLA Spec buy lonvo-z BLA filing notable
- 2H 2026 PALI Watch PALI-2108 CD IND filing notable
- 2H 2026 QNRX Spec buy QRX003 Ph2 readout notable
- 2H 2026 QNRX Spec buy QRX003 PSS Ph2 start notable
- 2H 2026 STRO Buy STRO-227 IND filing notable
- 2H 2026 VIR Buy VIR-5818 Ph1 readout notable
- 2H 2026 WVE Hold WVE-007 trial start notable
- 2H 2026 WVE Hold WVE-008 filing notable
- 2H 2026 ZBIO Spec buy Obexelimab MAA filing notable
- Late 2026 ABOS Spec buy Sabirnetug (ACU193) IV Ph2 topline thesis-defining
- late 2026 or early 2027 DRTS Spec buy Alpha DaRT SCC pivotal topline thesis-defining
- as early as the end of 2026 IMCR Spec buy Tebentafusp TEBE-AM topline thesis-defining
- By end of 2026 IMUX Watch vidofludimus calcium Ph3 topline thesis-defining
- by year-end 2026 KYMR Buy KT-621 BROADEN2 Ph2b topline thesis-defining
- late 2026 PMN Watch Sabirnetug Ph2 topline thesis-defining
- year-end 2026 or early 2027 TGTX Watch Subcutaneous ublituximab Ph3 topline thesis-defining
- year-end 2026 APVO Avoid Mipletamig Ph2 readout major
- Year-End 2026 BEAM Spec buy risto-cel BLA filing major
- late 2026 CLDX Buy Barzolvolimab Atopic Dermatitis Ph2 topline major
- year-end 2026 DTIL Watch PBGENE-HBV readout major
- Mid- and Late-2026 INAB Watch INB-200/INB-400 Ph2 interim major
- year-end 2026 ONCY Avoid REO 033 Part A interim major
- by year-end 2026 PRQR Spec buy AX-0810 Ph1 readout major
- by the end of 2026 ARDX Avoid Tenapanor ACCEL enrollment done notable
- late 2026 IMNM Watch IM-1335 IND filing notable
- Late 2026 INAB Watch INB-100 enrollment done notable
- year-end 2026 RLMD Watch NDV-01 IND filing notable
Next quarter · 1Q 2027 preview
48
quarter-precision or finer
- 1Q 2027 BMEA Spec buy Icovamenib topline thesis-defining
- 1Q 2027 BMEA Spec buy Icovamenib COVALENT-211 topline thesis-defining
- 1Q 2027 CBIO Buy CR-001 Ph1 topline thesis-defining
- 1Q 2027 MBRX Avoid Annamycin topline thesis-defining
- 1Q 2027 OCGN Watch OCU400 Ph3 topline thesis-defining
- 1Q 2027 PMN Watch PMN310 topline thesis-defining
- 1Q 2027 RNAC Buy Descartes-08 AURORA topline thesis-defining
- early 1Q 2027 TECX Watch TX45 topline thesis-defining
- 1Q 2027 TTRX Spec buy GX-03 eczema Ph2 topline thesis-defining
- 1Q 2027 XENE Hold Azetukalner MDD Ph3 topline thesis-defining
- 1Q 2027 AUTL Spec buy BOBCAT MS Ph1 interim major
- 1Q 2027 CGEN Watch COM701 interim major
- 1Q 2027 NAMS Watch PREVAIL obicetrapib readout major
- 1Q 2027 NKTR Watch Rezpegaldesleukin AD readout major
- 1Q 2027 ORKA Buy ORKA-002 Ph2 topline major
- Jan 2027 PRQR Spec buy AX-0811 Ph1 interim major
- 1Q 2027 SRPT Spec buy ELEVIDYS readout major
- 1Q 2027 SRPT Spec buy ELEVIDYS ENDEAVOR readout major
- 1Q 2027 AUTL Spec buy BOBCAT MS Ph2 readout material
- 1Q 2027 AXSM Watch Ecopipam Teva PDUFA date material
- 1Q 2027 CBIO Buy CR-003 / SKB105 Ph1 readout material
- 1Q 2027 DYN Buy z-basivarsen pivotal topline material
- 1Q 2027 FDMT Watch Ixo-vec ARTEMIS Ph3 topline material
- 1Q 2027 GANX Avoid GT-02287 Ph2 start material
- 1Q 2027 LENZ Spec buy VIZZ China decision material
- 1Q 2027 PMVP Spec buy Rezatapopt NDA filing material
- 1Q 2027 TECX Watch TX45 readout material
- 1Q 2027 VIR Buy ECLIPSE 2 and 3 topline material
- 1Q 2027 INBX Spec buy Ozekibart interim notable
- 1Q 2027 KZIA Watch Paxalisib colorectal Ph2 start notable
- Jan 2027 LQDA Watch YUTREPIA UTHR corporate update notable
- 1Q 2027 ONCY Avoid REO 033 Part B trial notable
- early 1Q 2027 PTGX Buy PN-881 Ph2b start notable
- 1Q 2027 PTGX Buy PN-8047 Ph1 start notable
- 1Q 2027 SLDB Spec buy SGT-212 Ph1 readout notable
- Jan 6, 2027 IBRX Buy Papillary-only sBLA PDUFA date material
- Jan 19, 2027 ONCY Avoid Common shares listing update notable
- Jan 21, 2027 DYN Buy z-rostudirsen FDA decision major
- Jan 28, 2027 INSM Watch ARIKAYCE FDA approval thesis-defining
- Feb 2027 IRON Watch Dersimelagon LEO PDUFA date material
- Feb 2027 – Sep 2028 PTGX Buy ICOTYDE readout material
- Feb 2027 LQDA Watch YUTREPIA SSc-RP readout notable
- Feb 3 – May 3, 2027 PRLD Watch JAK2V617F program Incyte option partnership material
- Feb 27, 2027 CGEM Buy Zipalertinib EGFR FDA decision major
- late 1Q 2027 TYRA Watch BEACH301 ACH readout notable
- Mar 3, 2027 EXEL Spec buy Zanzalintinib FDA approval material
- Mar 3, 2027 ONCY Avoid Zanzalintinib plus atezolizumab Exelixis PDUFA material
- Mar 10, 2027 BCRX Watch lonvo-z Intellia PDUFA date major
Further out · through 4Q 2027
82
the rest of the next twelve months, held to the same bar: quarter-precision or finer, or a wider window an outside source has confirmed
- Early 2027 ABSI Buy ABS-201 AGA topline thesis-defining
- 1H 2027 ACHV Watch Cytisinicline smoking cessation FDA approval thesis-defining
- 1H 2027 VOR Spec buy telitacicept Ph3 topline thesis-defining
- 1H 2027 ZNTL Spec buy Azenosertib topline thesis-defining
- early 2027 AKBA Spec buy AKB-9090 Ph1 topline major
- 2027 AXSM Watch solriamfetol SUSTAIN Ph3 topline major
- 2027 EVMN Watch EVO756 topline major
- 1H 2027 IMTX Hold anzu-cel SUPRAME Ph3 interim major
- 2027 MAIA Spec buy THIO-104 Ph3 interim major
- 1H 2027 RCUS Spec buy Quemliclustat Ph3 topline major
- 2027 RVMD Watch RASolve 301 daraxonrasib topline major
- 1H 2027 ZURA Watch Tibulizumab TibuSURE topline major
- 1H 2027 ACET Watch Prula-cel interim material
- 2027 JBIO Spec buy JADE201 Ph1 interim material
- 1H 2027 PCVX Buy VAX-31 infant Ph2 topline material
- 1H 2027 SANA Hold SG293 CAR-T readout material
- 1H 2027 SANA Hold SG293 readout material
- 1H 2027 ARVN Spec buy ARV-027 polyQ-AR readout notable
- 1H 2027 ENTX Watch EB612 IND filing notable
- 1H 2027 GLUE Buy MRT-8102 GFORCE-2 Ph2 start notable
- 2027 GLUE Buy CCNE1 MGD IND filing notable
- 2Q 2027 FDMT Watch 4D-150 4FRONT-1 AMD Ph3 topline thesis-defining
- 2Q 2027 MGTX Watch AAV-hAQP1 pivotal topline thesis-defining
- 2Q 2027 BMEA Spec buy Icovamenib COVALENT-212 topline major
- 2Q 2027 ADCT Watch ZYNLONTA + rituximab FL readout material
- Apr 1, 2027 HRMY Watch Pitolisant GR PDUFA date material
- Apr 2027 LQDA Watch Tyvaso UTHR FDA decision material
- Apr 2027 RNTX Watch Tyvaso nebulized PDUFA date material
- Apr 2027 RNTX Watch TETON-1/-2 United Therapeutics PDUFA date material
- 2Q 2027 TLSA Avoid Coya 302 ALS Ph2/3 topline material
- Apr 1, 2027 TLSA Avoid Intranasal foralumab MSA readout notable
- Apr 14, 2027 INBX Spec buy Ozekibart PDUFA date major
- Apr 23, 2027 BCRX Watch deucrictibant Pharvaris PDUFA date major
- Apr 28, 2027 IMNM Watch Varegacestat FDA decision major
- mid-2027 CRDL Hold CardiolRx MAVERIC topline thesis-defining
- mid-2027 ELOX Watch Exaluren NMAS topline thesis-defining
- by mid-2027 ELOX Watch Exaluren NMAS topline thesis-defining
- mid-2027 IMMX Buy NXC-201 Ph2 topline thesis-defining
- mid-2027 VRCA Spec buy YCANTH (VP-102) common warts topline thesis-defining
- May 1, 2027 AXSM Watch AXS-12 reboxetine PDUFA date major
- Mid-2027 CABA Buy RESET-Myositis pivotal topline major
- Mid-2027 CCCC Buy cemsidomide + elranatamab Ph1 readout major
- mid-2027 VSTM Spec buy Avutometinib + defactinib RAMP Ph3 major
- mid-2027 VTVT Spec buy CATT1 Ph3 topline major
- mid-2027 CBIO Buy CR-001 + Kelun-Biotech ADCs combination material
- mid-2027 IMMX Buy NXC-201 BLA filing notable
- as early as mid-2027 SANA Hold SG227 corporate update notable
- May 12, 2027 PTN Avoid Series J Warrants corporate update notable
- May 27, 2027 ZBIO Spec buy Obexelimab FDA approval material
- Jun 24, 2027 LQDA Watch Ralinepag UTHR PDUFA date material
- Jun 29, 2027 COGT Buy Bezuclastinib AdvSM PDUFA date thesis-defining
- Jun 29, 2027 IVVD Avoid PEMGARDA FDA decision major
- 2H 2027 ARDX Avoid Tenapanor ACCEL Ph3 topline thesis-defining
- 3Q 2027 BCRX Watch navenibart topline thesis-defining
- 3Q 2027 CRVS Buy Soquelitinib Atopic Dermatitis Ph2 topline thesis-defining
- 2H 2027 MPLT Spec buy ML-007C-MA VISTA Ph2 topline thesis-defining
- 2H 2027 NGNE Spec buy NGN-401 topline thesis-defining
- 2H 2027 OVID Spec buy OV329 topline thesis-defining
- 2H 2027 PALI Watch PALI-2108 UC topline thesis-defining
- 2H 2027 SABS Spec buy SAB-142 topline thesis-defining
- 2H 2027 SCYX Watch SCY-770 Ph2 topline thesis-defining
- 2H 2027 XNCR Spec buy XmAb942 UC topline thesis-defining
- 2H 2027 BIOA Hold BGE-102 DME Ph1 topline major
- 2H 2027 FDMT Watch 4D-150 4FRONT-2 AMD Ph3 topline major
- 2H 2027 IPSC Spec buy CNTY-813 topline major
- 2H 2027 PCVX Buy VAX-A1 Ph1 topline material
- Jul 2027 BCRX Watch ORLADEYO corporate update notable
- 2H 2027 ETON Buy ASN-001 NDA filing notable
- Jul 2027 KZIA Watch Paxalisib TNBC enrollment done notable
- 3Q 2027 NRSN Avoid PrimeC Ph3 start notable
- 3Q 2027 NRSN Avoid PARAGON trial start notable
- 2H 2027 REPL Buy RP1 interim notable
- Jul 2027 TLSA Avoid Intranasal foralumab ALS readout notable
- 3Q 2027 TLSA Avoid Amlenetug MSA Ph3 readout notable
- Jul 14, 2027 BCAX Watch '968 Patent PTAB Review FDA material
- Aug 30, 2027 ONCY Avoid REO 033 topline thesis-defining
- Late-2027 KYMR Buy KT-621 BREADTH Ph2b topline thesis-defining
- end of 2027 TENX Watch TNX-103 enrollment done notable
- Sep 30, 2027 ANNX Watch loan tranche corporate update notable
- Oct 2027 DYN Buy Hercules covenant FDA approval material
- 4Q 2027 EYPT Hold COMO/CAPRI DME topline material
- Oct 2027 PRLD Watch Menarini MEN2312 Ph1 readout notable
How to read this
Deeper blue means more of the thesis turns on the event — not a view on the stock and not a prediction of the outcome. A thesis-defining readout and a routine trial start are both just events until they report.
Dates reflect company guidance as reported in Biotech Distilled coverage and are frequently windows rather than fixed dates. Not investment advice.